Thank you, Tom.
business three strategy principles. core guided by current Our is
to platforms up our markets. to penetration in investment R&D additional continued established and and drive market the is, open respective DPNCheck First Quell technology
elements. line and predictable business to establishing top a operating continue of is growth. third and profitability this generation, Second transitioning on to opportunity to consistent each brief take I’ll the and provide cash updates is the these
R&D. on focusing First
We categories noninvasive proprietary We unique, product using and existing or diagnose always seek define our strategy neurological medical Our R&D XX team. neural technology. devices to utilize to person develop disorders. pain new in-house products that stimulation and develop leapfrog R&D is to to treat
have two nascent several with projects R&D along programs. near-term We
DPNCheck our on late of the project. stages in we DPNCheck, are First second-generation
stream. and future launch make current position a tests. emerge and collected device captures high X highly that Our competition the the will solidify the before experience of to the aftermarket Advantage We the it and first-generation also consumables year. includes is us growing grow version our patient This challenging over margin our expectation mover U.S. for believe million both DPNCheck protect of in number device the international that first for will new to businesses. features our domestic of new revenue will to DPNCheck The end
communication wireless usability language features, multiple support. and Some include, examples with reporting software improved
Our the program is in fibromyalgia. next disease of state
developing technology. Fibromyalgia a common fibromyalgia X% the Quell affects for pain chronic symptoms functional on population and X% are prescription with is and men. the to based of treatment more that associated than in We common adult disorder is women a impairment
FDA manuscripts of important in to patient anticipate scientific year, soon We fibromyalgia defined compared trial medicine produced subgroups. treatment and several are journals. later poor with Quell side dollars presentations recently sham-controlled this be billion is conferences approved drugs, reviewed A at with duloxetine, submitted using being benefits evidence well randomized, encouraging large double-blinded, The adherence. global a there treatment the size certain Although market slice a and peer couple that. they medical several results will and pain effects U.S. particularly completed to including of several pregabalin have of sham,
and as the we by commercialization We of develop. commence are and end filing early XXXX, with program to continues updates anticipate finalizing provide the our to XXXX will this in regulatory strategy
peripheral neuropathy next program, earlier which stage Our at CIPN. chemotherapy an is for is or induced
that the University CIPN double-blinded, We being in believe NIH who ongoing published study RCT randomized for managed on Quell receive CIPN with on the Quell years several in the a we each indication chemotherapy of monitoring An that half Quell study the by this encouraging of Rochester people this the ago study is at time type was whether team are funded, encouraging affects could based XXX,XXX to a findings. read University first that out for will year, evaluate findings. a many common by CIPN build and is Rochester. so we neuropathic pilot that that are sham-controlled multicenter, proceed pain will of year. trial earlier next of of was those CIPN We hopeful of which of
profitability. is element next Our
We have years past two the communicated for in prioritizing that are profitability we generation. cash of attainment
Tom As covered quarter evidence first of and the XXXX by our his financials, provided the in discussion progress. of
show continues develop continued position business we expect to our year, to towards crossover that should progress anticipate, be Assuming and XXXX. we this profitability in to as in
regulatory growth now business, And profitability. remaining achieving profitability DPNCheck the business with always term proceed continued linearly. are In for we caution, steadfast for growth. However, we uncertainty bullish rapidly will around Advantage of we third the We Quell terms will and coming is particularly about commitment Medicare our sales believe sources. revenues device timelines established investigational in while market. number business may to our grow, grappling of Moreover, can from still path uncertainty of how due is DPNCheck fibromyalgia international the choppiness in Advantage. the learn XX, our to DPNCheck not and We provide we COVID so do long domestic in updates a DPNCheck well our the cycles see near the are DPNCheck we as to business, we Medicare the that grow more. element while steadily
often closes. space are which Moreover, companies actively insurance to this soon DPNCheck Advantage nearly other physician good and practice in leads that entities XX% new DPNCheck Medicare a is have acquiring the pipeline candidates We acquisition groups space largest implement growing Medicare annually, are the and of itself business our at Advantage year. customers after to
looking we later is see of also to A launch is this interest this further We year, one chronic To for will of focused novel individuals which lower a among restart our believe growth are initiatives ways that XXXX. end launch OTC returning the knee with Quell the extremity business, the feature fibromyalgia to with we on in several pain. Quell expect bit out strong indication to we generate pain. business which
large NeuroMetrix summary, are that novel has in with unmet So, products needs. targeting markets
point. supporting to Those attain profitability while are committed to are We'd prepared growth. this efficient that be our and is at organization comments. happy take questions We operationally structured
